Clinical trials: Recent Myocardial Infarction
Acute Myocardial Infarction
MiSaver® Stem Cell Treatment for Acute Myocardial Infarction
Despite advancements in treatments, cardiovascular diseases, especially acute myocardial infarction (AMI), remain significant health concerns.
- Trial name
- MiSaver® (NCT06353958)
- Testing
- MiSaver
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Honya Medical Inc
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes.
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Trial name
- NCT07619885
- Testing
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
Primary Objective The primary objective of this study is to evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular…
- Trial name
- NCT00555828
- Testing
- Allogeneic Mesenchymal Precursor Cells (MPCs), Standard-of-care treatment with NOGA® mapping and staged injections.
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Angioblast Systems
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 821 sites in United States, Australia and 43 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.